Primary_CNS_lymphoma_treated_with_osmotic_blood-brain_barrier_disruption:_prolonged_survival_and_preservation_of_cognitive_function._Combination_chemotherapy_with_or_without_radiotherapy_has_had_only_modest_efficacy_in_the_treatment_of_primary_CNS_lymphoma._Median_survival_of_these_patients,_treated_primarily_with_radiotherapy,_is_13_months;_5-year_survival_is_less_than_5%._Thirty_consecutive_non-acquired_immune_deficiency_syndrome_patients_with_primary_CNS_lymphoma_were_treated_with_barrier-dependent_chemotherapy_using_intraarterial_mannitol_to_open_the_blood-brain_barrier_(BBB)._Follow-up_included_extensive_neuropsychologic_testing_of_all_patients._Thirteen_patients_received_cranial_radiation_1_to_9_months_before_referral_(group_1)._Seventeen_patients_received_initial_BBB_disruption_chemotherapy_with_subsequent_radiation_only_for_tumor_progression_or_recurrence_(group_2)._The_difference_in_median_survivals_from_diagnosis--17.8_months_for_group_1_and_44.5_months_for_group_2--was_statistically_significant_(P_=_.039)._Group_1_survival_is_comparable_with_the_20-month_median_survival_of_a_historical_series_of_patients_(n_=_208)_treated_with_radiotherapy_with_or_without_chemotherapy._Group_2_patient_survival_represents_an_advance_in_the_survival_of_CNS_lymphoma_and_was_associated_with_preservation_of_cognitive_function_in_six_of_seven_nonirradiated_complete_responders_observed_for_1_to_7_years._Patient_toxicity_was_manageable_in_this_intensive_therapeutic_regimen._In_this_series,_a_plateau_in_survival_curves_suggests_that_a_major_portion_of_these_patients_may_be_cured_without_the_neuropsychologic_sequelae_associated_with_cranial_radiation.